Radiosurgery for paraganglioma of the temporal bone.
OBJECTIVE
To report the outcome of patients with paraganglioma of the temporal bone treated with stereotactic radiosurgery at the University of Florida.


METHODS
Between January 1997 and June 1999, five patients with paraganglioma of the temporal bone were treated with Linac-based stereotactic radiosurgery at the University of Florida. The ages of the three female and two male patients were between 40 and 88 years (median, 49 years). Four patients were treated at initial presentation, and one had recurrent disease. Treatment volumes ranged from 4.9 cm3 to 18.4 cm3, with a mean of 10.84 cm3. The dose applied to the margin of the tumor varied from 12.5 to 15 Gy (median, 15 Gy). The treatment dose was specified to the 80% isodose shell in two cases and to the 70% isodose shell in three cases. The median follow-up time was 27 months, ranging from 14 to 50 months.


RESULTS
One of four previously untreated patients had a relapse at the primary tumor site. Treatment failure occurred at the field margin 6 months after radiosurgery; the patient was subsequently treated with fractionated stereotactic radiotherapy and at the time of analysis had no evidence of disease, 21 months after initiation of salvage therapy. The patient treated at the time of recurrence after conventional radiotherapy had a local recurrence 40 months after radiosurgery. At the time of this recurrence, the patient had biopsy-proven metastatic disease in two cervical lymph nodes, and no salvage therapy was performed. All patients were alive at the time of the analysis, one with disease present. Presenting symptoms improved in two patients and stabilized in one. The two patients who had local recurrence develop had worsening of their symptoms. One patient had a cranial nerve V palsy develop 6 months after treatment, which resolved after a few months.


CONCLUSIONS
In this series, the results with stereotactic radiosurgery are discouraging compared with our results with conventional fractionated radiotherapy in patients with paraganglioma of the temporal bone.
Feigenberg
Steven J
SJ
Department of Radiation Oncology, University of Florida Health Science Center, PO Box 100385, Gainesville, FL 32610-0385, USA.
Mendenhall
William M
WM
Hinerman
Russell W
RW
Amdur
Robert J
RJ
Friedman
William A
WA
Antonelli
Patrick J
PJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010235:Paraganglioma / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery*; D016634:Radiosurgery / Q000009:adverse effects; D012888:Skull Neoplasms / Q000517:prevention & control / Q000532:radiotherapy / Q000601:surgery*; D013701:Temporal Bone / Q000601:surgery*; D016896:Treatment Outcome